IRIS
RENI, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.310
EU - Europa 9.575
AS - Asia 9.032
SA - Sud America 2.645
Continente sconosciuto - Info sul continente non disponibili 588
AF - Africa 200
OC - Oceania 10
Totale 32.360
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.633
RU - Federazione Russa 5.272
SG - Singapore 3.013
CN - Cina 2.787
BR - Brasile 2.187
IT - Italia 1.834
HK - Hong Kong 1.109
VN - Vietnam 990
SE - Svezia 844
FR - Francia 461
BD - Bangladesh 420
CA - Canada 340
DE - Germania 313
GB - Regno Unito 243
AR - Argentina 187
IN - India 171
FI - Finlandia 148
MX - Messico 118
NL - Olanda 96
ID - Indonesia 81
ZA - Sudafrica 81
EC - Ecuador 80
PL - Polonia 72
JP - Giappone 59
IQ - Iraq 56
CO - Colombia 54
TR - Turchia 48
ES - Italia 47
IE - Irlanda 46
AT - Austria 45
CR - Costa Rica 40
JM - Giamaica 40
PY - Paraguay 37
VE - Venezuela 35
PK - Pakistan 33
UA - Ucraina 33
CL - Cile 29
MA - Marocco 28
HN - Honduras 25
MY - Malesia 24
AE - Emirati Arabi Uniti 22
EG - Egitto 22
UZ - Uzbekistan 22
IL - Israele 19
NI - Nicaragua 19
PE - Perù 19
JO - Giordania 17
KE - Kenya 17
PH - Filippine 16
RO - Romania 16
SV - El Salvador 16
GT - Guatemala 15
TT - Trinidad e Tobago 15
AL - Albania 14
NP - Nepal 14
SA - Arabia Saudita 14
TH - Thailandia 14
TN - Tunisia 14
CW - ???statistics.table.value.countryCode.CW??? 13
LT - Lituania 13
PR - Porto Rico 13
AZ - Azerbaigian 12
IR - Iran 12
CZ - Repubblica Ceca 11
BB - Barbados 10
BH - Bahrain 10
DZ - Algeria 10
KZ - Kazakistan 10
LB - Libano 10
KR - Corea 9
AU - Australia 8
BE - Belgio 8
UY - Uruguay 8
EU - Europa 7
OM - Oman 7
PS - Palestinian Territory 7
PT - Portogallo 7
BO - Bolivia 6
CH - Svizzera 6
CI - Costa d'Avorio 6
EE - Estonia 6
MD - Moldavia 6
BY - Bielorussia 5
DK - Danimarca 5
DO - Repubblica Dominicana 5
PA - Panama 5
BS - Bahamas 4
HU - Ungheria 4
NG - Nigeria 4
QA - Qatar 4
XK - ???statistics.table.value.countryCode.XK??? 4
BG - Bulgaria 3
CY - Cipro 3
KW - Kuwait 3
LV - Lettonia 3
SN - Senegal 3
YE - Yemen 3
AM - Armenia 2
AO - Angola 2
BA - Bosnia-Erzegovina 2
Totale 31.743
Salva come PNG Salva come JPEG
Città #
Singapore 1.286
Moscow 1.281
Ashburn 1.275
Dallas 1.271
Hong Kong 1.097
San Jose 984
Shanghai 481
Council Bluffs 480
Milan 426
Hefei 420
Ho Chi Minh City 368
Lauterbourg 367
Phoenix 354
Princeton 349
Lawrence 342
Beijing 306
Santa Clara 297
New York 273
São Paulo 201
Hanoi 200
Los Angeles 162
Rome 160
Helsinki 100
Boardman 84
Nuremberg 82
Miano 81
Munich 73
Orem 72
Rio de Janeiro 72
Montreal 69
Naples 69
Chicago 68
Warsaw 62
Atlanta 57
Seattle 57
Boston 54
Toronto 53
Mexico City 51
Buffalo 49
London 47
Johannesburg 46
Belo Horizonte 45
Denver 45
Tokyo 44
Dublin 43
Brooklyn 42
Guangzhou 42
Haiphong 42
North Bergen 42
Chennai 39
Campinas 38
Houston 38
Cesano Boscone 37
Poplar 37
Stockholm 36
Da Nang 35
Turku 34
Brasília 33
Miami 33
Bologna 32
Porto Alegre 32
Washington 31
Amsterdam 30
Dhaka 29
San José 29
Biên Hòa 28
Manchester 28
Philadelphia 28
The Dalles 28
Quito 27
Brescia 26
Frankfurt am Main 26
Kingston 25
Mumbai 25
Tianjin 25
Catania 24
Curitiba 24
Hangzhou 24
Guayaquil 23
Turin 23
Palermo 22
San Francisco 22
Las Vegas 21
Tashkent 21
Columbus 20
Guarulhos 20
Florence 19
Barnet 18
Changsha 18
Charlotte 18
Genoa 18
Hải Dương 18
Managua 18
Shenzhen 18
Vienna 18
Ankara 17
Asunción 17
Bogotá 17
Caxias do Sul 17
Queens 17
Totale 15.272
Salva come PNG Salva come JPEG
Nome #
Exploring machine learning tools in a retrospective case-study of patients with metastatic non-small cell lung cancer treated with first-line immunotherapy: A feasibility single-centre experience 251
Clinical Relevance of the Dose of Cytarabine in the Upfront Treatment of Primary CNS Lymphomas with Methotrexate-Cytarabine Combination 224
Endoscopic ultrasound-guided choledochoduodenostomy versus hepaticogastrostomy combined with gastroenterostomy in malignant double obstruction (CABRIOLET_Pro): A prospective comparative study 212
Postoperative Outcomes and Functional Recovery After Preoperative Combination Chemotherapy for Pancreatic Cancer: A Propensity Score-Matched Study 206
Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by the Italian Association of Medical Oncology (AIOM) 187
EUS-guided GastroEnterostomy for management of malignant Gastric Outlet Obstruction: a prospective cohort study with matched comparison with Enteral Stenting 178
(Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial 177
A multicenter study of treatment of primary CNS lymphoma 176
Ependymoma 174
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen). 166
A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma 163
Linee guida AIOM per le neoplasie cerebrali. 162
An integrated clinical pathway for pancreatic and periampullary tumor management within the Pancreas Unit network in Lombardy, Italy 160
A Comprehensive Characterization of Stemness in Cell Lines and Primary Cells of Pancreatic Ductal Adenocarcinoma 159
Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatment - Risk factors analysis 159
Communication, understanding and engagement of patients with pancreatic cancer at time of diagnosis 155
Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocarcinoma 150
A four-step method to centralize pancreatic surgery, accounting for volume, performance and access to care 150
Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants 146
A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer 146
Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial 146
A preoperative score to predict early death after pancreatic cancer resection 145
Chemotherapy in elderly patients with pancreatic cancer: Efficacy, feasibility and future perspectives 143
Diagnostic and therapeutic management of neuroendocrine lung tumors. A clinical study of 44 cases 143
DIAGNOSTIC DELAY AT DIAGNOSIS AND TIME-TO-TREATMENT INFLUENCE OVERALL SURVIVAL OF PANCREATIC CANCER PATIENTS 142
A MULTICENTER TRIAL ASSESSING FEASIBILITY AND EFFICACY OF A COMBINATION OF HIGH-DOSE METHOTREXATE, CYTARABINE AND THIOTEPA IN PATIENTS WITH PRIMARY CNS LYMPHOMA: IMPACT ON OUTCOME OF CYTARABINE DOSE 140
Randomized phase 2 study of valproic acid combined with simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic pancreatic adenocarcinoma patients: the VESPA trial study protocol 139
A pilot study of chlorambucil in pre-treated metastatic pancreatic adenocarcinoma patients bearing germline BRCA or other DNA damage repair system variants 137
Exploring the optimal therapeutic management of stage ypIA pancreatic ductal adenocarcinoma patients in the era of primary chemotherapy 134
A systematic review of surgical resection of liver-only synchronous metastases from pancreatic cancer in the era of multiagent chemotherapy 132
A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile 131
A multicenter study of the prognosis and treatment of adult brain ependymal tumors 130
The role of biliary events in treatment and survival of patients with advanced pancreatic ductal adenocarcinoma 127
Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients 127
Ex-vivo investigation of radiofrequency ablation in pancreatic adenocarcinoma after neoadjuvant chemotherapy 126
Anatomically resectable versus biologically borderline resectable pancreatic cancer definition: refining the border beyond anatomical criteria and biological aggressiveness 124
Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma 124
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial 123
ASO Visual Abstract: Very Early Recurrence After Curative Resection for Pancreatic Ductal Adenocarcinoma: Proof of Concept for a "Biologic R2 Definition" 123
A randomized phase II trial of adjuvant chemotherapy with cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG regimen) or gemcitabine alone after curative resection for pancreatic cancer 122
The Impact of CT-Assessed Liver Steatosis on Postoperative Complications After Pancreaticoduodenectomy for Cancer 121
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: Results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial 120
A phase II trial of second-line therapy with trabectedin in metastatic pancreatic adenocarcinoma 120
ASO Visual Abstract: The Impact of CT-Assessed Liver Steatosis on Postoperative Complications After Pancreaticoduodenectomy for Cancer 119
Early intravenous administration of nutritional support (IVANS) in metastatic gastric cancer patients at nutritional risk, undergoing first-line chemotherapy: study protocol of a pragmatic, randomized, multicenter, clinical trial 119
A MULTICENTER RETROSPECTIVE STUDY OF CHEMOTHERAPY IN ADULTS WITH EPENDYMOMA. GICNO (GRUPPO ITALIANO COOPERATIVO NEURO-ONCOLOGIA) 118
Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial 117
Quaderni dell’infermiere-Neurologia III edizione 117
Preoperative mFOLFIRINOX versus PAXG for stage I–III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial 114
Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma 114
Corneal and Epidermal Nerve Quantification in Chemotherapy Induced Peripheral Neuropathy 114
A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients 114
Cyclophosphamide maintenance to extend combination chemotherapy-free interval in metastatic pancreatic ductal adenocarcinoma 113
COMMUNI.CARE (COMMUNIcation and Patient Engagement at Diagnosis of PAncreatic CAncer): Study Protocol 113
A phase II trial of PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced gallbladder, biliary tract, and ampulla of Vater adenocarcinoma, preliminary results 113
Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey 112
Prediction of early distant recurrence in upfront resectable pancreatic adenocarcinoma: A multidisciplinary, machine learning-based approach 112
Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial 111
RNA Extraction from Endoscopic Ultrasound-Acquired Tissue of Pancreatic Cancer Is Feasible and Allows Investigation of Molecular Features 111
A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-Oncologia 111
EUS-guided gallbladder drainage and subsequent peroral endoscopic cholecystolithotomy: A tool to reduce chemotherapy discontinuation in neoplastic patients? 110
Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies 110
Pathologic complete response following neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma: Impact on survival and recurrence 110
Efficacy of endoscopic ultrasound-guided ablation with the hybridtherm probe in locally advanced or borderline resectable pancreatic cancer: A phase ii randomized controlled trial 110
Sex dimorphism and cancer immunotherapy: May pregnancy solve the puzzle? 109
Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer 108
A RANDOMIZED PHASE II TRIAL OF TWO DIFFERENT FOUR DRUG COMBINATIONS IN ADVANCED PANCREATIC ADENOCARCINOMA: CISPLATIN, CAPECITABINE, GEMCITABINE PLUS EITHER EPIRUBICIN OR DOCETAXEL 108
Very Early Recurrence After Curative Resection for Pancreatic Ductal Adenocarcinoma: Proof of Concept for a “Biological R2 Definition” 108
Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes 107
An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study 107
ENDOSCOPIC ULTRASOUND-GUIDED HYBRID THERM ABLATION (EUS-HTP) IN PATIENTS (PTS) WITH LOCALLY ADVANCED (LA) PANCREATIC DUCTAL ADENOCARCINOMA (PDAC): A CASE-CONTROL COMPARATIVE SURVIVAL ANALYSIS 107
3D conformal radiotherapy significantly reduces toxicity of post-prostatectomy adjuvant or salvage irradiation 106
Adjuvant Chemoradiation in Pancreatic Cancer: A Pooled Analysis in Elderly (≥75 years) Patients 105
REDISCOVER guidelines for borderline-resectable and locally advanced pancreatic cancer: management algorithm, unanswered questions, and future perspectives 105
Clinical signature and pathogenetic factors of diabetes associated with pancreas disease (T3cDM): a prospective observational study in surgical patients 103
Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic ductal adenocarcinoma patients 103
Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients 103
Landscape of Health-Related Quality of Life in Patients with Early-Stage Pancreatic Cancer Receiving Adjuvant or Neoadjuvant Chemotherapy: A Systematic Literature Review 102
Prognosis of Upfront Surgery for Pancreatic Cancer: A Systematic Review and Meta-Analysis of Prospective Studies 102
Adjuvant PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) or Gemcitabine Followed by Chemoradiation in Pancreatic Cancer: A Randomized Phase II Trial 102
Lessons and open questions in borderline resectable pancreatic cancer 101
Treatment sequences and prognostic/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world study in Europe 100
Evolving pancreatic cancer treatment: From diagnosis to healthcare management 100
Isolated lung metastases from pancreatic ductal adenocarcinoma (PDAC): Diagnostic and therapeutic challenges of a different disease 99
ASO Visual Abstract: Proposal for a New Pathologic Prognostic Index After Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma 98
Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey 98
A retrospective analysis of postradiation chemotherapy in 133 patients with glioblastoma multiforme 98
Therapeutic management of refractory or relapsed primary central nervous system lymphomas 98
Survival analysis of the non-metastatic cohort of the Italian Association for Medical Oncology (AIOM) Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy (GARIBALDI) 97
The impact of nutritional status on pancreatic cancer therapy 97
Overall Survival With Adjuvant mFOLFIRINOX for Pancreatic Cancer 97
Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas 97
Necrosis volume and Choi criteria predict the response to endoscopic ultrasonography-guided HybridTherm ablation of locally advanced pancreatic cancer 97
Adjuvant chemotherapy in ductal adenocarcinoma of pancreas: a comparison among three regimens 97
Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas 97
Survival analysis of the metastatic cohort of Italian Association of Medical Oncology (AIOM) GARIBALDI survey. 97
Neoadjuvant chemoradiotherapy in patients with esopageal or esophageal gastric junction cancer 96
Nomogram for Estimating Overall Survival in Patients with Metastatic Pancreatic Cancer 95
Circulating Chromogranin A Is Cleaved Into Vasoregulatory Fragments in Patients With Pancreatic Ductal Adenocarcinoma 95
A retrospective series of upfront therapy in primary brain lymphomas 95
Totale 12.536
Salva come PNG Salva come JPEG
Categoria #
all - tutte 193.081
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 193.081
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022329 0 0 0 30 10 2 5 232 18 5 8 19
2022/20231.774 786 437 54 14 13 220 50 92 51 17 23 17
2023/2024871 53 52 88 93 84 132 26 86 23 35 56 143
2024/20255.355 652 118 88 131 165 457 635 453 971 827 397 461
2025/202618.121 1.181 1.384 1.790 2.521 1.239 414 1.370 1.257 4.821 911 562 671
2026/20275.847 1.232 1.469 1.114 2.032 0 0 0 0 0 0 0 0
Totale 32.360